Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...
Sen. Bernie Sanders questions Novo Nordisk CEO Lars Jorgensen in a hearing on Capitol Hill about the high prices Americans pay for Ozempic and Wegovy compared with people in other countries.